Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
QTRX
QTRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
QTRX News
Quanterix Submits Blood Test for Alzheimer's Disease to FDA
Feb 03 2026
Newsfilter
Quanterix Publishes Landmark Alzheimer’s Study with C-Index of 0.90
Jan 21 2026
Businesswire
Rich Sparkle Holdings Signs $39 Million Share Offering Agreement
Jan 09 2026
Benzinga
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
Jan 09 2026
Benzinga
Quanterix Appoints Everett Cunningham as New CEO Effective January 19, 2026
Jan 08 2026
Businesswire
Quanterix Unveils Leadership and Board Changes to Facilitate Future Growth
Nov 20 2025
Newsfilter
Quanterix Unveils Pioneering Study Showcasing Dual GFAP/NfL Blood Test Method for Tailored Monitoring of Multiple Sclerosis
Nov 17 2025
Newsfilter
Quanterix Corp Reports Wider Q3 Loss, Falls Short of Expectations
Nov 11 2025
NASDAQ.COM
Quanterix Gains Ground Following CMS Pricing Approval for LucentAD Alzheimer Blood Biomarker Test
Sep 10 2025
SeekingAlpha
Quanterix Accelerator Laboratory Receives Strict New York State Clinical Laboratory License
Aug 21 2025
Newsfilter
Canaccord Genuity Downgrades Quanterix to Hold, Lowers Price Target to $5
Aug 11 2025
Benzinga
Quanterix Announces Cooperation Agreement with Kent Lake Capital
Aug 04 2025
Newsfilter
Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC
Jul 28 2025
Newsfilter
Quanterix Completes Akoya Acquisition, Expands Biomarker Reach To $5 Bln Market
Jul 09 2025
NASDAQ.COM
Quanterix Expands Reach with IVD and Large Reference Labs
Jun 23 2025
Newsfilter
Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders
Jun 11 2025
PRnewswire
Show More News
